Expression of miR-490-3p in gastric cancer and its clinical value

doi:10.3877/cma.j.issn.1674-0793.2023.01.011

Abstract

Abstract:

Objective

To investigate the relationship between the expression of miR-490-3p clinicopathological features and prognosis of gastric cancer.

Methods

The relative expression of miR-490-3p in cancer tissues and adjacent normal tissues of 80 patients with gastric cancer were detected by quantitative real-time PCR (qPCR), and the relationship between it and clinicalpathological characteristics was analyzed. Kaplan-Meier curve and Cox proportional risk regression model were used for prognostic analysis.

Results

The relative expression of miR-490-3p in cancer tissues was (0.652±0.072), which was lower than (1.259±0.069) of normal adjacent tissues, with a statistically significant difference (t=40.528, P<0.05). The expression of miR-490-3p was significantly correlated with the depth of invasion, lymph node metastasis and TMN staging (P<0.05). There was a significant difference in progression free survival between patients with low expression and high expression (23 months vs 30 months, χ²=8.583, P=0.03). miR-490-3p, lymph node metastasis and TNM stage were independent prognostic factors of gastric cancer (HR=2.396, 0.472, 0.230, all P<0.05).

Conclusion

The down-regulation of miR-490-3p may promote the proliferation, differentiation and migration of gastric cancer, and may become a potential molecular marker for the diagnosis and prognosis of gastric cancer.

Key words: miR-490-3p, Gastric neoplams, Clinicopathological features, Prognosis

Song Tao, Yakui Liu, Yi Shi, Guolei Song, Shuanhu Wang. Expression of miR-490-3p in gastric cancer and its clinical value[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 55-58.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.01.011

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I01/55

Figures/Tables 4

References 12

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Lazăr DC, Avram MF, Romoșan I, et al. Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer[J]. World J Gastroenterol, 2018, 24(32): 3583-3616.
[3]	Li Y, Tian D, Chen H, et al. MicroRNA-490-3p and -490-5p in carcinogenesis: separate or the same goal?[J]. Oncol Lett, 2021, 22(3): 678.
[4]	Li J, Mo R, Zheng L. MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2[J]. World J Surg Oncol, 2021, 19(1): 117.
[5]	Zhang LY, Liu M, Li X, et al. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3)[J]. J Biol Chem, 2013, 288(6): 4035-4047.
[6]	Shen J, Xiao Z, Wu WK, et al. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis[J]. Cancer Res, 2015, 75(4): 754-765.
[7]	Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions[J]. Brief Bioinform, 2014,15(1): 1-19.
[8]	Kang NN, Ge SL, Zhang RQ, et al. MiR-490-3p inhibited the proliferation and metastasis of esophageal squamous cell carcinoma by targeting HMGA2[J]. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8298-8305.
[9]	Lu N, Zhang M, Lu L, et al. miRNA-490-3p promotes the metastatic progression of invasive ductal carcinoma[J]. Oncol Rep, 2021, 45(2): 706-716.
[10]	Liu X, He B, Xu T, et al. MiR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer[J]. J Cancer, 2018, 9(7): 1218-1230.
[11]	张文静, 吴克俭, 谭宁平. 早期胃癌淋巴结转移的危险因素及预后分析[J]. 中国中西医结合消化杂志, 2020, 28(5): 331-337.
[12]	Qin D, Wei R, Zhu S, et al. MiR-490-3p silences CDK1 and inhibits the proliferation of colon cancer through an LLPS-dependent miRISC system[J]. Front Mol Biosci, 2021, 8: 561678.

引物名称	引物序列（5’→3’）
miR-490-3p forward	GAAGGGTAGATTTAGGCTGTAT
miR-490-3p reverse	CAGTTGAGAAAAAGTTATGCACT
U6 forward	CCCTATTTTTGACGCGTTATGTGA
U6 reverse	GTGAAAATTACAGGGTCATTTGTG

引物名称	引物序列（5’→3’）
miR-490-3p forward	GAAGGGTAGATTTAGGCTGTAT
miR-490-3p reverse	CAGTTGAGAAAAAGTTATGCACT
U6 forward	CCCTATTTTTGACGCGTTATGTGA
U6 reverse	GTGAAAATTACAGGGTCATTTGTG

项目		例数	高表达组	低表达组	χ²值	P值
例数		80	32	48
性别					0.889	0.346
	男	50	22	28
	女	30	10	20
年龄(岁)					0.366	0.545
	≥60	57	24	33
	<60	23	8	15
肿瘤直径(cm)					0.076	0.783
	≥5	44	17	27
	<5	36	15	21
分化程度					0.079	0.779
	中、高分化	31	13	18
	低分化	49	19	30
肿瘤部位					0.335	0.562
	贲门、胃底	27	12	15
	胃窦、胃体	53	20	33
浸润深度					5.275	0.022^a
	T₁+T₂	28	16	12
	T₃+T₄	52	16	36
淋巴结转移					6.601	0.014^a
	有	55	17	38
	无	25	15	10
TNM分期					6.243	0.012^a
	Ⅰ+Ⅱ	31	18	13
	Ⅲ+Ⅳ	49	14	35

项目		例数	高表达组	低表达组	χ²值	P值
例数		80	32	48
性别					0.889	0.346
	男	50	22	28
	女	30	10	20
年龄(岁)					0.366	0.545
	≥60	57	24	33
	<60	23	8	15
肿瘤直径(cm)					0.076	0.783
	≥5	44	17	27
	<5	36	15	21
分化程度					0.079	0.779
	中、高分化	31	13	18
	低分化	49	19	30
肿瘤部位					0.335	0.562
	贲门、胃底	27	12	15
	胃窦、胃体	53	20	33
浸润深度					5.275	0.022^a
	T₁+T₂	28	16	12
	T₃+T₄	52	16	36
淋巴结转移					6.601	0.014^a
	有	55	17	38
	无	25	15	10
TNM分期					6.243	0.012^a
	Ⅰ+Ⅱ	31	18	13
	Ⅲ+Ⅳ	49	14	35

因素	β	SE	Wald	P	HR	95% CI
因素	β	SE	Wald	P	HR	上限	下限
miR-490-3p	0.874	0.341	6.561	0.010	2.396	1.228	4.675
浸润深度	-0.430	0.752	0.326	0.568	0.651	0.149	2.842
淋巴结转移	-0.750	0.284	6.979	0.008	0.472	0.271	0.824
TNM分期	-1.471	0.519	8.024	0.005	0.230	0.083	0.635

Please choose a citation manager

Content to export